Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma

被引：3

作者：

Grosicki, Sebastian ^{[1
]}

Barchnicka, Agnieszka ^{[2
]}

机构：

[1] Silesian Med Univ, Sch Publ Hlth, Dept Canc Prevent, Katowice, Poland

[2] Med Univ Silesia, Sch Publ Hlth Bytom, Dept Doctoral Studies, Katowice, Poland

来源：

EXPERT REVIEW OF HEMATOLOGY | 2016年 / 9卷 / 07期

关键词：

Multiple myeloma; monoclonal antibody treatment; elotuzumab; efficacy; safety; immune-stimulating therapy; LENALIDOMIDE PLUS DEXAMETHASONE; NATURAL-KILLER-CELL; HUMANIZED MONOCLONAL-ANTIBODY; TERM-FOLLOW-UP; DOSE DEXAMETHASONE; OPEN-LABEL; BORTEZOMIB; CS1; CYTOTOXICITY; COMBINATION;

D O I：

10.1080/17474086.2016.1199947

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Multiple myeloma (MM), constantly remains debilitating disease, consequently leading to death. Clinical trials involving drugs with different mechanisms of action, carry the expectancy for improvement of treatment outcomes. The results of the currently published studies on the monoclonal antibodies, in particular elotuzumab confirm previous expectations of improving treatment outcomes of such therapy in MM patients.Areas covered: This humanized monoclonal antibody targeting surface glycoprotein CS1, expressed commonly on plasma cells and certain cells of the immune system, stimulates the immune system to fight against MM cells. Elotuzumab in the combination with len/dex has been approved by the FDA for treatment of relapsed/refractory MM patients who have received one to three prior therapies.Expert commentary: This review summarizes the chemistry, mechanism of action and preclinical and clinical studies, pharmacodynamics, pharmacokinetics, safety and toxicity of elotuzumab in terms of MM treatment and its potential application in the future.

引用

页码：621 / 628

页数：8

共 46 条

[1]

[Anonymous], COLD SPRING HARB PER

[2] Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways [J].

Balasa, Balaji ;

Yun, Rui ;

Belmar, Nicole A. ;

Fox, Melvin ;

Chao, Debra T. ;

Robbins, Michael D. ;

Starling, Gary C. ;

Rice, Audie G. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (01) :61-73

[3] Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences [J].

Barlogie, Bart ;

Attal, Michel ;

Crowley, John ;

van Rhee, Frits ;

Szymonifka, Jackie ;

Moreau, Philippe ;

Durie, Brian G. M. ;

Harousseau, Jean-Luc .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1209-1214

[4] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].

Benson, Don M., Jr. ;

Bakan, Courtney E. ;

Mishra, Anjali ;

Hofmeister, Craig C. ;

Efebera, Yvonne ;

Becknell, Brian ;

Baiocchi, Robert A. ;

Zhang, Jianying ;

Yu, Jianhua ;

Smith, Megan K. ;

Greenfield, Carli N. ;

Porcu, Pierluigi ;

Devine, Steven M. ;

Rotem-Yehudar, Rinat ;

Lozanski, Gerard ;

Byrd, John C. ;

Caligiuri, Michael A. .

BLOOD, 2010, 116 (13) :2286-2294

[5] SLAM Family Receptors and SAP Adaptors in Immunity [J].

Cannons, Jennifer L. ;

Tangye, Stuart G. ;

Schwartzberg, Pamela L. .

ANNUAL REVIEW OF IMMUNOLOGY, VOL 29, 2011, 29 :665-705

[6] Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC [J].

Collins, Shauna M. ;

Bakan, Courtney E. ;

Swartzel, Gina D. ;

Hofmeister, Craig C. ;

Efebera, Yvonne A. ;

Kwon, Hakju ;

Starling, Gary C. ;

Ciarlariello, David ;

Bhaskar, Shakthi ;

Briercheck, Edward L. ;

Hughes, Tiffany ;

Yu, Jianhua ;

Rice, Audie ;

Benson, Don M., Jr. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (12) :1841-1849

[7] Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function [J].

Cruz-Munoz, Mario-Ernesto ;

Dong, Zhongjun ;

Shi, Xiaochu ;

Zhang, Shaohua ;

Veillette, Andre .

NATURE IMMUNOLOGY, 2009, 10 (03) :297-305

[8] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors [J].

de Weers, Michel ;

Tai, Yu-Tzu ;

van der Veer, Michael S. ;

Bakker, Joost M. ;

Vink, Tom ;

Jacobs, Danielle C. H. ;

Oomen, Lukas A. ;

Peipp, Matthias ;

Valerius, Thomas ;

Slootstra, Jerry W. ;

Mutis, Tuna ;

Bleeker, Wim K. ;

Anderson, Kenneth C. ;

Lokhorst, Henk M. ;

van de Winkel, Jan G. J. ;

Parren, Paul W. H. I. .

JOURNAL OF IMMUNOLOGY, 2011, 186 (03) :1840-1848

[9] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J].

Dimopoulos, Meletios ;

Spencer, Andrew ;

Attal, Michael ;

Prince, H. Miles ;

Harousseau, Jean-Luc ;

Dmoszynska, Anna ;

San Miguel, Jesus ;

Hellmann, Andrzej ;

Facon, Thierry ;

Foa, Robin ;

Corso, Alessandro ;

Masliak, Zvenyslava ;

Olesnyckyj, Marta ;

Yu, Zhinuan ;

Patin, John ;

Zeldis, Jerome B. ;

Knight, Robert D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2123-2132

[10] Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial [J].

Facon, Thierry ;

Mary, Jean Yves ;

Hulin, Cyrille ;

Benbouker, Lofti ;

Attal, Michel ;

Pegourie, Brigitte ;

Renaud, Marc ;

Guillerm, Jean Luc Harousseau Gaelle ;

Ahletaix, Carine ;

Dib, Mamoun ;

Voillat, Laurent ;

Maisonneuve, Herve ;

Troncy, Jacques ;

Dervaux, Weronique ;

Monconduit, Mathieu ;

Martin, Claude ;

Casassus, Philippe ;

Jaubert, Jerome ;

Jardel, Henry ;

Doyen, Chantal ;

Kolb, Brigitte ;

Anglaret, Bruno ;

Grosbois, Bernard ;

Yakoub-Agha, Ibrahim ;

Mathiot, Claire ;

Avet-Loiseau, Herve .

LANCET, 2007, 370 (9594) :1209-1218

← 1 2 3 4 5 →